ejpmr, 2025, 12(4), 145-156

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

SJIF Impact Factor

Review Article

ISSN 2394-3211

EJPMR

ADVANCES IN PHARMACOLOGICAL MANAGEMENT OF ALCOHOL WITHDRAWAL SYNDROME

Pakala Akhila Reddy, Mekala Anusha*, Banevath Abhilash, Akarapu Pavan Kalyan, Gummadaveli Rithwick Mani, Muvvala Sudhakar

India.

***Corresponding Author: Mekala Anusha**

India.

Article Received on 06/02/2025 **Article Revised on 26/02/2025** **Article Accepted on 18/03/2025**

ABSTRACT

Alcohol Withdrawal Syndrome (AWS) occurs when chronic alcohol consumption is abruptly stopped, leading to significant distress and health risks. It results from an imbalance between GABA and NMDA receptors, causing symptoms ranging from mild anxiety to severe seizures and delirium tremens. While benzodiazepines remain the primary treatment, emerging pharmacological targets—such as corticotropin-releasing factor, sigma receptors, opioid receptors, potassium channels, ghrelin, and gut microbiota—offer potential alternatives. This review explores the pathophysiology, neurobiological mechanisms, and advancements in AWS treatment, highlighting novel therapeutic strategies that could improve clinical outcomes.

KEYWORD: Alcohol Withdrawal Syndrome (AWS), Neurotransmitters, GABA, NMDA Receptors, Benzodiazepines, Alternative Therapies, Corticotropin-Releasing Factor, Opioid Receptors, Potassium Channels, Gut Microbiota, Pharmacological Management.

INTRODUCTION

Alcohol withdrawal syndrome (AWS) occurs when an individual who has engaged in heavy and prolonged alcohol consumption either reduces or ceases alcohol intake, leading to the onset of at least two symptoms within hours to a few days. These symptoms include autonomic hyperactivity, tremors in the hands, difficulty sleeping, nausea or vomiting, temporary sensory disturbances (Such as visual, auditory, or tactile hallucinations), heightened psychomotor activity, anxiety, or generalized tonic-clonic seizures.[1] Approximately half of individuals with alcohol use disorder (AUD) may experience withdrawal symptoms upon reducing alcohol consumption.[2]

The development of AWS is attributed to neuroadaptive changes in the central nervous system caused by chronic alcohol consumption. This results in a downregulation of GABAergic receptors and an upregulation of glutamatergic receptors.[1,3] Consequently, when alcohol intake suddenly stops, the central nervous system enters a hyperexcitable state, leading to symptoms that range from mild tremors and anxiety to more severe conditions such as seizures and delirium tremens (DT), which can affect up to 5% of AWS patients.[4,5]

AWS is frequently observed in hospitalized patients and, if left untreated, can be life-threatening.[6-8] Despite its prevalence, there is a lack of high-quality evidence to guide treatment strategies for managing AWS in inpatient settings. The syndrome primarily arises due to an imbalance between the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and the excitatory neurotransmitter glutamate. Chronic alcohol use leads to a decrease in GABA receptor activity and a compensatory increase in N-methyl-D-aspartate (NMDA) receptor activity, which binds glutamate. When alcohol is abruptly removed, the central nervous system is flooded with excitatory glutamate, exacerbating withdrawal symptoms. The primary goal of treatment is to prevent the progression to DT by restoring neurochemical balance. Benzodiazepines (BZDs) remain the primary treatment due to their ability to enhance GABA A receptor function. More recently, phenobarbital has gained attention as an alternative treatment, as it not only enhances GABA A receptor activity but also inhibits glutamate, potentially addressing benzodiazepine resistance.[9]

Research on inpatient AWS treatments is limited due to small study sizes and the exclusion of patients with significant medical or surgical comorbidities.[10-14] despite these conditions frequently co-occurring in hospitalized and critically ill patients. AWS presents on a spectrum of neurophysiological symptoms, which are influenced by the severity of AUD and other underlying

medical conditions that impact brain signalling pathways.[15-17] Additionally, AWS has been linked to prolonged intensive care unit (ICU) and hospital stays, an increased risk of hospital-acquired infections and sepsis, and higher in-hospital mortality rates.[18-21]

Epidemiology

The overall prevalence of alcohol withdrawal in the general population is relatively low, with an estimated 5% of U.S. adults experiencing it in 1995. However, rates are significantly higher among individuals undergoing detoxification and rehabilitation for alcohol dependence, reaching as much as 86%.[22] A national survey conducted in the UK in 2002 revealed that hazardous drinking was self-reported by 38% of male respondents and 23% of female respondents, defined as consuming five or more drinks for men and three or more drinks for women on a typical drinking day.[23]

In medical settings, the prevalence of alcohol abuse or dependence is even greater, with approximately 20% of hospital inpatients affected and up to 40% of individuals seeking care in Accident and Emergency (A&E) departments.[24-25] The financial impact of alcohol misuse on the UK economy is substantial, with an estimated cost to the National Health Service (NHS) of £1.5 billion in 2000/2001. Alcohol-related issues accounted for a significant proportion of healthcare burdens, contributing to approximately one in every 26 hospital bed days.[26] Despite the widespread impact of alcohol misuse, dedicated alcohol specialists were present in only 12.8% of NHS general hospitals in 2000 and 2003.[27] Additionally, there has been limited development of comprehensive guidelines to assist healthcare providers in managing and treating alcohol withdrawal syndrome (AWS).[28-30]

Pathophysiology

The acute consumption of ethanol suppresses central nervous system (CNS) activity by enhancing GABAergic neurotransmission while simultaneously reducing glutamatergic activity.[31-33] However, prolonged alcohol use leads to an adaptive recalibration of neurotransmitter systems, including GABA, glutamate, and norepinephrine, ultimately contributing to the development of alcohol tolerance.[34-36]

When alcohol intake is abruptly reduced or discontinued, blood ethanol levels drop, resulting in diminished GABAergic activity and heightened glutamatergic activity. This disruption creates neuronal hyperexcitability, which manifests as symptoms of alcohol withdrawal syndrome (AWS). These symptoms can include neuropsychiatric complications such as seizures and delirium tremens (DT), driven by autonomic nervous system hyperactivity.[34,37] Furthermore, repeated episodes of withdrawal can lead to a phenomenon known as "kindling," where cumulative neuronal excitability results in progressively more severe AWS over time.[38,39]



The prediction of alcohol withdrawal syndrome severity scale

The Alcohol Withdrawal Severity Scale Prediction (PAWSS) is the 10 most important clinical characteristics found in the comprehensive literature review were used to develop the PAWSS, which is linked to the creation of AWS. There are three components to PAWSS: (A) the threshold criteria, which determine whether the patient drank alcohol within 30 days prior to admission and/or had a positive blood alcohol level (BAL) upon admission; (B) a series of 10 Yes/No questions from the patient interview; and (C) clinical evidence, which evaluates known risk factors for withdrawal and current clinical status (refer to Fig: PAWSSTool). Because a patient who has not consumed alcohol in the 30 days prior to the visit is thought to be beyond the window for withdrawal and unlikely to have AWS, regardless of whether the patient has an AUD, the threshold question was added. (Hall & Zador, 1997; Schuckit, 2009); no further PAWSS questions are posed after then. If a patient does, in fact, endorse recent alcohol consumption (i.e., within the last 30 days), the second section of the PAWSS will ask 10 questions that evaluate established risk factors for withdrawal and current clinical status.

Since the literature indicates that clinical interviews can yield the most accurate information on alcohol abuse and relapse when compared to collateral information or specific laboratory data (such as BAL), the PAWSS is primarily based on patients' self-reports of alcohol intake and history (Cherpitel et al., 2007; Di Martini et al., 2001).[40]

Prediction of Alcohol Withdrawal Severity Scale (PAWSS)

Maldonado et al, 2015

Part A: Threshold Criteria: ("Y" or "N", no point)

Have you consumed any amount of alcohol (i.e., been drinking) within the last 30 days? OR did the patient have a "+" BAL on admission? _____

IF the answer to either is YES, proceed with test:

Part B: Based on patient interview: (1 point each)

1. Have you been recently intoxicated/drunk, within the last 30 days? _____
2. Have you ever undergone alcohol use disorder rehabilitation treatment or treatment for alcoholism? (i.e., in-patient or out-patient treatment programs or AA attendance) _____
3. Have you ever experienced any previous episodes of alcohol withdrawal, regardless of severity? _____
4. Have you ever experienced blackouts? _____
5. Have you ever experienced alcohol withdrawal seizures? _____
6. Have you ever experienced delirium tremens or DT's? _____
7. Have you combined alcohol with other "downers" like benzodiazepines or barbiturates, during the last 90 days? _____
8. Have you combined alcohol with any other substance of abuse, during the last 90 days? _____

Part C: Based on clinical evidence: (1 point each)

9. Was the patient's blood alcohol level (BAL) on presentation ≥ 200? _____
10. Is there evidence of increased autonomic activity? (e.g., HR > 120 bpm, tremor, sweating, agitation, nausea) _____

Total Score: _____

Notes: Maximum score = 10. This instrument is intended as a SCREENING TOOL. The greater the number of positive findings, the higher the risk for the development of AWS.
A score of ≥ 4 suggests HIGH RISK for moderate to severe (complicated) AWS; prophylaxis and/or treatment may be indicated.

Alcohol withdrawal syndrome: Treatment

Goals of the treatment

The primary goals of treating alcohol withdrawal syndrome (AWS) are to alleviate withdrawal symptoms, prevent complications such as seizures and delirium tremens (DT), reduce the risk of mortality, and support the patient in achieving long-term abstinence from alcohol. Prompt and appropriate intervention not only lessens the severity of current withdrawal episodes but also decreases the likelihood of future occurrences and relapse into alcohol use.[41]

Seizures associated with alcohol withdrawal typically emerge between 24 to 72 hours after the last alcohol intake. These seizures are generally tonic-clonic in nature and usually last for less than five minutes. Approximately one-third of AWS patients who experience seizures may progress to DT, a severe and potentially life-threatening condition. DT is linked to an increased risk of death, with certain factors heightening the risk, including prolonged heavy alcohol consumption, being over 30 years old, extended time since the last drink, and a history of DT episodes.

Hallucinations, particularly visual in nature, are a common symptom of AWS. While they can be distressing for patients, they are not inherently dangerous. Individuals experiencing DT require inpatient care for proper monitoring and treatment. Given that AWS symptoms can be exacerbated by external stimuli, patients should be managed in a calm and low-stimulation environment. Those with mild withdrawal symptoms may only need supportive care.

Psychological interventions alone are not effective in preventing seizures or DT. Most patients with AWS receive pharmacological treatment, particularly when there is uncertainty regarding their ability to maintain long-term abstinence from alcohol.[42-44]

Management of alcohol withdrawal syndrome

The treatment of alcohol withdrawal syndrome (AWS) involves both pharmacological management and supportive care. Supportive care includes paramedic assistance, minimizing environmental stressors such as

bright lights and loud noises, maintaining orientation to reality, and providing counselling.[45]

Pharmacological management focuses on stabilizing the patient by correcting biochemical imbalances, which commonly include electrolyte disturbances, dehydration, hypoglycaemia, and deficiencies in essential vitamins, particularly B vitamins and folate. Additionally, any existing comorbidities should be appropriately managed.

Benzodiazepines are considered the gold standard for treating AWS symptoms due to their effectiveness in reducing the risk of complications, including seizures, delirium tremens (DT), and mortality.[46-48] Their efficacy is attributed to their action on GABA-A receptors, whose function is significantly impaired following abrupt alcohol cessation.[49] Research indicates that long-acting benzodiazepines, such as chlordiazepoxide and diazepam, are particularly effective due to their prolonged effects, which stem both from the parent compounds and their active metabolites.[50-51] These metabolites undergo hepatic glucuronidation (Phase II metabolism) before being eliminated by the kidneys.

In cases of liver dysfunction, short-acting benzodiazepines, such as oxazepam and lorazepam, are preferred to minimize the risk of excessive sedation and respiratory depression, as they do not require oxidative metabolism in the liver.[46] Benzodiazepines offer multiple administration routes, though intramuscular injection is generally avoided due to poor absorption. The choice of administration route depends on the severity of symptoms—intravenous administration is recommended for moderate to severe cases, while oral administration is sufficient for mild cases that do not require hospitalization.

The Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) scale is a useful tool for evaluating symptom severity and guiding appropriate treatment decision.[52]

Advances in pharmacological management of alcohol withdrawal syndrome

Benzodiazepines

Benzodiazepines play a crucial role in managing alcohol withdrawal syndrome (AWS) by alleviating symptoms and reducing the risk of withdrawal-related seizures. These medications are available in both long-acting forms, such as chlordiazepoxide (Librium) and diazepam (Valium), and intermediate-acting forms, including lorazepam (Ativan) and oxazepam. Long-acting benzodiazepines are often preferred for preventing delirium tremens due to their extended sedative and anxiolytic effects, which result from active metabolites that provide prolonged symptom relief. Some experts suggest that these longer-acting medications help stabilize withdrawal with fewer fluctuations in symptoms. However, intermediate-acting benzodiazepines have also been successfully used in managing withdrawal.[53-54]

For patients with liver dysfunction, intermediate-acting benzodiazepines are considered safer, as they do not produce active metabolites that require hepatic metabolism. Certain benzodiazepines, such as diazepam, alprazolam (Xanax), and lorazepam, tend to be preferred by individuals with substance use disorders, though they carry a higher risk of misuse.[55] In contrast, chlordiazepoxide and oxazepam have a lower potential for abuse, although there is no clear evidence that they are more effective in treating AWS.[56] Due to the risk of respiratory depression and fatal outcomes when benzodiazepines are combined with alcohol, healthcare providers should emphasize the importance of complete alcohol abstinence as part of treatment.[57]

Table 1. Fixed and Symptom-Triggered Dosing for Oral Benzodiazepines[a]

Medication	Fixed Schedule	Symptom-Triggered Schedule[b]
Day 1		
Diazepam	10 mg every 6 h	10-20 mg every 4 h
Chlordiazepoxide	25-50 mg every 6 h	25-100 mg every 4 h
Lorazepam	2 mg every 8 h	2-4 mg every 6 h
Day 2		
Diazepam	10 mg every 8 h	10-20 mg every 6 h
Chlordiazepoxide	25-50 mg every 8 h	25-100 mg every 6 h
Lorazepam	2 mg every 8 h	2-4 mg every 6 h
Day 3		
Diazepam	10 mg every 12 h	10-20 mg every 6 h
Chlordiazepoxide	25-50 mg every 12 h	25-100 mg every 6 h
Lorazepam	1 mg every 8 h	1-4 mg every 8 h
Day 4		
Diazepam	10 mg at bedtime	10-20 mg every 12 h
Chlordiazepoxide	25-50 mg at bedtime	25-100 mg every 12 h
Lorazepam	1 mg every 12 h	1-4 mg every 12 h
Day 5		
Diazepam	10 mg at bedtime	10-20 mg every 12 h
Chlordiazepoxide	25-50 mg at bedtime	25-100 mg every 6 h
Lorazepam	1 mg at bedtime	1-4 mg every 12 h

[a] For patients with a Clinical Institute for Withdrawal Assessment for Alcohol—revised (CIWA-Ar) score >9.
[b] Additional doses/medications may be needed if symptoms are not controlled at selected doses.
Source: References 10, 13, 22.

Benzodiazepines can be administered using either a fixed-dose or symptom-triggered approach. A loading-dose regimen, where high doses are initially given, is generally not recommended. In the fixed-dose method, a predetermined amount of medication is administered at scheduled intervals, regardless of symptom severity, with additional doses provided as needed to control withdrawal symptoms. The dosage is then gradually reduced if signs of overmedication appear.[58] In contrast, the symptom-triggered approach involves administering medication only when significant withdrawal symptoms are present, typically indicated by a Short Alcohol Withdrawal Scale (SAWS) score of 12 or higher or a Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) score above 9. This method has been shown to reduce overall medication use and shorten the duration of inpatient treatment.[59] However, a study on outpatients receiving long-acting benzodiazepines found no significant difference between the two approaches in terms of total medication use, patient satisfaction, or time to relapse. The effectiveness of symptom-triggered regimens relies on accurate symptom assessment by both patients and caregivers, which may not always be feasible in every clinical setting.[60]

Anticonvulsants

Carbamazepine (Tegretol) and valproic acid (Depakene) may have potential benefits in managing alcohol withdrawal syndrome (AWS), although supporting evidence is limited.[61-62] Carbamazepine use is associated with side effects such as dizziness, ataxia, double vision, nausea, and vomiting.[63] Research has indicated that carbamazepine is more effective than lorazepam in preventing early relapse within 12 days of follow-up.[64] However, there is minimal data supporting valproic acid as a superior alternative to benzodiazepines.[65]

Oxcarbazepine (Trileptal) has shown comparable effectiveness to carbamazepine in treating AWS in some studies, but a randomized controlled trial found it no more effective than a placebo in alleviating withdrawal symptoms.[66-67] Gabapentin (Neurontin) has been found to be as effective as lorazepam in managing AWS and reducing alcohol consumption during withdrawal. While anticonvulsants have a lower risk of abuse compared to benzodiazepines, they do not offer protection against seizures or delirium tremens.[68]

Table

Anticonvulsant regimens for treating alcohol withdrawal

Gabapentin	400 mg, every 8 hours, for 3 days, then 400 mg, twice a day, for 1 day or may be continued indefinitely for relapse prevention[1]
Carbamazepine	400 mg, twice a day, taper to 200 mg over 5 days[2]
Divalproex	500 mg, every 8 hours, for 7 days to augment as-needed benzodiazepines

Skeletal muscle relaxant

Baclofen

Baclofen, a GABA-B receptor agonist, functions as a modulator of the γ-aminobutyric acid (GABA) system. It has been officially approved for alcohol use disorder (AUD) treatment in France since 2018[69] and has been prescribed off-label for this purpose in several other countries, particularly in Europe and Australia, for over a decade. However, clinical trials evaluating baclofen's effectiveness have produced inconsistent findings.[70-71]

A recent meta-analysis of 12 randomized controlled trials (RCTs) involving 703 participants found that baclofen increased abstinence rates compared to placebo. However, it did not significantly impact other outcomes such as abstinent days, cravings, heavy drinking, depression, or anxiety.[72-75] Another meta-analysis of 13 RCTs with 1,492 participants suggested that baclofen was associated with a longer time to relapse and a higher percentage of abstinent individuals, particularly among those with greater alcohol consumption at baseline. In contrast, a separate meta-analysis of 12 RCTs with 1,128 participants reported no meaningful differences between baclofen and placebo in terms of key outcomes, including abstinent days, heavy drinking days, relapse rates, and study retention. Additionally, baclofen use was linked to an increase in depression and adverse effects such as sedation and vertigo.[76]

Notable side effects of baclofen include drowsiness, sedation, headaches, dizziness, confusion, excessive sweating, muscle rigidity, abnormal movements, slurred speech, and numbness.[77-78] Long-term use may lead to tolerance, and increasing the dose to compensate can heighten sedative effects, particularly in women. Abrupt discontinuation or dose reduction can trigger withdrawal symptoms that may be life-threatening.[79-81] The variability in baclofen's efficacy across studies may be influenced by pharmacokinetic differences among

individuals with AUD, which remains a critical factor in its clinical use.

Some evidence suggests that baclofen may be particularly beneficial for AUD patients with liver disease.[82—84] Overall, while baclofen has shown promise in promoting abstinence, its effects on other clinical outcomes, including reducing heavy drinking, remain uncertain. The drug's significant side effects and individual variability in response further contribute to the ongoing debate regarding its role and optimal dosing in AUD treatment.[85]

Table 2. Medications Used to Treat Alcohol Withdrawal Syndrome (AWS)

Medication	Typical Single Dose	FDA-Approved for AWS	Common Adverse Effects
Benzodiazepines			
Alprazolam	0.5-1.0 mg	No	Sedation, fatigue, ataxia, respiratory depression, retrograde amnesia, dependence and abuse
Chlordiazepoxide	25-50 mg	Yes	
Diazepam	10 mg	Yes	
Lorazepam	2 mg	No	
Oxazepam	15-30 mg	Yes	
Anticonvulsants			
Carbamazepine	600-800 mg	No	Dizziness, ataxia, diplopia, nausea, vomiting
Gabapentin	300-600 mg	No	
Oxcarbazepine	450-900 mg	No	
Valproic acid	1,000-1,200 mg	No	
Skeletal Muscle Relaxant			
Baclofen	10 mg	No	Hypotension, constipation, nausea, vomiting, asthenia, dizziness, headache, somnolence
Beta-blocker			
Atenolol	50-100 mg	No	Bradycardia, hypotension, fatigue, dizziness, depression
Alpha-Adrenergic Agonist			
Clonidine	0.2 mg	No	Hypotension, dry mouth, dizziness, constipation, sedation

Source: References 10, 13, 21-22, 25-28.

Beta-Blockers

Beta-blockers, such as atenolol, can be used to alleviate hyperarousal symptoms in individuals with coronary artery disease.[86] However, due to their effects on reducing tremors, tachycardia, and hypertension, they have the potential to mask symptoms of alcohol withdrawal syndrome (AWS). Therefore, beta-blockers should only be used alongside benzodiazepines in patients who continue to experience persistent hypertension or tachycardia.[87]

Alpha 2 Agonists

Alpha-2 agonists, such as dexmedetomidine and clonidine, help reduce norepinephrine release, thereby alleviating the sympathetic symptoms of alcohol withdrawal syndrome (AWS), including tremors, agitation, tachycardia, and hypertension.[88] A randomized trial comparing flunitrazepam with haloperidol to clonidine in AWS patients found that while clonidine was associated with fewer pneumonia cases and reduced time on mechanical ventilation, it also carried a higher risk of cardiac complications.[89]

Dexmedetomidine has been investigated as an adjunctive treatment for AWS, with evidence suggesting it can lower benzodiazepine requirements, enhance sedation and patient communication, decrease the need for haloperidol, and shorten hospital stays.[90-94] However, like clonidine, it poses a higher risk of cardiovascular side effects, such as bradycardia and hypotension. Given these findings, dexmedetomidine may be a valuable option for AWS patients who require high doses of benzodiazepines or barbiturates and continue to experience significant sympathetic symptoms.[90-92]

Other medications

Barbiturates

Chronic heavy alcohol use can lead to changes in the GABA receptor subunit, potentially reducing the effectiveness of benzodiazepines due to increased alcohol tolerance and cross-tolerance. As a result, phenobarbital has gained interest as a primary treatment option or as an adjunct therapy for alcohol withdrawal syndrome (AWS).[93] Unlike benzodiazepines, phenobarbital has a longer half-life and functions differently by prolonging GABA-A receptor activation while also inhibiting glutamate transmission via AMPA signalling. These pharmacological properties make it particularly beneficial for managing moderate-to-severe AWS, especially in patients who require high benzodiazepine doses or exhibit tolerance to them.

Some studies suggest that using phenobarbital alone or alongside benzodiazepines may lead to reduced benzodiazepine use, fewer ICU admissions, shorter hospital stays, lower reliance on physical restraints, and decreased rates of intubation and mechanical ventilation.[94-96] However, a separate meta-analysis found no significant difference between benzodiazepines and phenobarbital in terms of clinical outcomes.

When using phenobarbital, front-loading strategies should be considered. A weight-based dosing approach (5 to 10 mg/kg IV over 30 minutes) has been shown to be both safe and effective for AWS management, with some patients requiring additional doses up to a total of 15 mg/kg. If phenobarbital is introduced alongside benzodiazepines or if there is a delay in the initial loading dose, incremental IV doses of 130 to 260 mg every 15 to 30 minutes can be administered as needed.[97-98]

Neuroleptics

Neuroleptics, such as haloperidol, are primarily utilized for managing hallucinations and delirium. However, they do not prevent the progression of alcohol withdrawal syndrome (AWS) and may increase the risk of seizures and QT prolongation. Due to these risks, neuroleptics should not be used as monotherapy. Additionally, their use has been linked to prolonged delirium, higher rates of complications, and increased mortality.[99] Therefore, neuroleptics should only be considered as an adjunctive treatment for agitation, perceptual disturbances, or disorganized thinking that is not adequately managed with benzodiazepines.[100]

Valproate

Valproic acid (400–500 mg three times daily) has been shown to improve alcohol withdrawal syndrome (AWS) symptoms in a dose-dependent manner.[101] It may also help reduce the risk of seizures and prevent the worsening of AWS severity due to its anti-kindling properties. These characteristics make valproic acid a promising option for outpatient management of mild-to-moderate AWS.[102] However, common side effects include gastrointestinal discomfort, tremors, and sedation. Additionally, its potential to elevate liver enzyme levels (transaminases) may limit its use in individuals with alcohol-related liver impairment.[103]

Sodium oxybate

Sodium oxybate (SMO), also known as gamma-hydroxybutyric acid, is a naturally occurring short-chain fatty acid found in various regions of the mammalian brain, including the thalamus, hypothalamus, and basal ganglia. Structurally similar to the inhibitory neurotransmitter GABA, SMO binds with high affinity to its own receptors and with lower affinity to GABA-B receptors. Due to its alcohol-like effects on the central nervous system, SMO has been studied in both preclinical and clinical settings for its potential in managing alcohol withdrawal syndrome (AWS).[104]

Comparative studies have demonstrated the effectiveness of repeated doses of SMO (50 mg/kg/day in three divided doses) when compared to benzodiazepines and clomethiazole for treating AWS. Most clinical trials assessing SMO in AWS patients have used the reduction of the CIWA-Ar score and its sub-scores as key measures of efficacy. A 2010 meta-analysis by The Cochrane Collaboration found that SMO (50 mg/kg/day) was more effective than placebo in reducing AWS symptoms and was comparable in efficacy to benzodiazepines and clomethiazole, with similar side effect profiles and dropout rates.

The GATE 1 study, a phase IV multicenter, multinational, randomized, double-blind trial, confirmed SMO's effectiveness and demonstrated its non-inferiority to oxazepam in AWS treatment. Given its established efficacy and safety in long-term alcohol dependence management, SMO is considered valuable for both AWS treatment and relapse prevention.[105] Some European countries have approved SMO for these indications, while other nations have not, primarily due to concerns about its potential for abuse. However, at therapeutic doses for alcohol-dependent patients, the risk of misuse appears to be relatively low. Further research is needed to better understand these aspects and refine its clinical application.

Gabapentin

Gabapentin is a medication structurally similar to GABA and is approved as an adjunct treatment for partial seizures. Its primary mechanism appears to involve enhancing GABA synthesis in the brain. However, the effectiveness of gabapentin in managing alcohol withdrawal syndrome (AWS) remains uncertain.

Early clinical studies suggest that gabapentin may be beneficial for individuals experiencing AWS, with a dosing schedule of 400 mg three times daily for three days, followed by 400 mg twice daily for one day, and 400 mg once daily for another day.[106] A retrospective analysis of both outpatient and inpatient cases indicated that gabapentin was effective in treating mild-to-moderate AWS but showed limited efficacy in more severe cases. Additionally, recent research has demonstrated that gabapentin may be both safe and effective in managing tonic-clonic seizures associated with AWS.

An open-label study involving 27 inpatients compared gabapentin to phenobarbital and found no significant difference in effectiveness between the two drugs. However, a double-blind, placebo-controlled trial did not show gabapentin to be more effective than placebo in treating AWS, possibly due to an insufficient initial dose.

Further studies are necessary to confirm gabapentin's role in AWS treatment. If its efficacy is validated, gabapentin could become a valuable option not only for

managing AWS but also for preventing alcohol relapse in patients with alcohol dependence.[107]

Topiramate

Topiramate is an anticonvulsant that works through several mechanisms. It enhances GABA-A receptor activity and acts as an antagonist to AMPA/kainate receptors for glutamate, which leads to a reduction in dopamine release in the nucleus accumbens. Additionally, it modulates ion channels by inhibiting L-type calcium channels, reducing the effects of voltage-sensitive sodium channels, and enhancing potassium conduction. These combined actions help topiramate reduce the hyperactivity and anxiety associated with alcohol withdrawal syndrome (AWS).[108]

Open-label studies have shown that topiramate (50 mg twice daily or once daily) can be effective in reducing the occurrence of seizures and other symptoms related to AWS.[109] Its ability to influence multiple neurotransmitter systems supports its use in treating AWS. Given the promising preliminary data on topiramate's effectiveness in managing AWS and promoting alcohol abstinence, it could become a valuable treatment option for alcohol use disorder, ranging from AWS management to long-term detoxification.[110]

SUMMARY AND CONCLUSION

Summary

The article "Advances in Pharmacological Management of Alcohol Withdrawal Syndrome" explores the complex pathophysiology, epidemiology, and treatment strategies for Alcohol Withdrawal Syndrome (AWS). AWS arises due to neuroadaptive changes following chronic alcohol consumption, leading to an imbalance between inhibitory (GABA) and excitatory (glutamate) neurotransmitter systems. This results in symptoms ranging from mild anxiety to severe conditions like delirium tremens (DT) and seizures.

The article highlights the prevalence of AWS, especially in hospitalized patients and those undergoing detoxification. Despite its significant impact, effective inpatient treatment guidelines remain limited. Pharmacological management focuses on restoring neurochemical balance and preventing complications. Benzodiazepines remain the gold standard for treatment due to their effectiveness in enhancing GABA activity. However, alternative treatments such as barbiturates, anticonvulsants (carbamazepine, valproic acid, gabapentin, topiramate), skeletal muscle relaxants (baclofen), and other neuromodulators are explored as potential therapeutic options.

Recent advancements in AWS treatment have also introduced novel pharmacological targets, including corticotropin-releasing factor, sigma receptors, opioid receptors, potassium channels, ghrelin, endocannabinoid receptors, and gut microbiota. The article reviews emerging therapies that may provide more effective and safer alternatives to traditional benzodiazepine-based treatments, especially in patients with comorbidities or resistance to standard interventions.

CONCLUSION

AWS is a serious medical condition that requires prompt diagnosis and appropriate management to prevent severe complications such as seizures and delirium tremens. While benzodiazepines remain the primary treatment, alternative and adjunctive therapies, including barbiturates, anticonvulsants, baclofen, beta-blockers, alpha-2 agonists, and newer molecular targets, show promise in improving outcomes. Future research should focus on individualized treatment approaches that account for patient-specific factors, including liver function, addiction history, and risk of relapse. Developing more targeted pharmacological strategies could lead to improved management of AWS and better long-term recovery outcomes for individuals struggling with alcohol dependence.

REFERENCES

1. Lolk A. Neurokognitive lidelser. InDiagnostic and statistical manual of mental disorders. American Psychiatric Association, 2013.
2. Schuckit MA. Alcohol-usedisorders. Lancet, 2009; 373(9662): 492-501.
3. Long D, Long B, Koyfman A. The emergency medicine management of severe alcohol withdrawal. The American journal of emergency medicine, 2017; 1, 35(7): 1005-11.
4. Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). New England Journal of Medicine, 2014; 27, 371(22): 2109-13.
5. Schmidt KJ, Doshi MR, Holzhausen JM, Natavio A, Cadiz M, Winegardner JE. Treatment of severe alcohol withdrawal. Annals of Pharmacotherapy, 2016; 50(5): 389-401.
6. Mc Keon A, Frye MA, Delanty N. Thealco holwithd rawalsy ndrome. J Neurol Neurosurg Psychiatry, 2008; 79: 854–862.
7. Monte R, Rabuñal R, Casariego E, López-Agreda H, Mateos A, Pértega S. Analysis of the factors determining survival of alcoholic withdrawal syndrome patients in a general hospital. Alcohol & Alcoholism, 2010; 1, 45(2): 151-8.
8. Steel TL, Malte CA, Bradley KA, Lokhandwala S, Hough CL, Hawkins EJ. Prevalence and variation of clinically recognized inpatient alcohol withdrawal syndrome in the Veterans Health Administration. Journal of addiction medicine, 2020; 1, 14(4): 300-4.
9. Rosenson J, Clements C, Simon B, Vieaux J, Graffman S, Vahidnia F, Cisse B, Lam J, Alter H. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. The Journal of emergency medicine, 2013; 1, 44(3): 592-8.

10. AmatoL, Minozzi S, Davoli M. Efficacyands afetyofphar macological intervention nsforthet reatmento fthealcoho lwithdrawa lsyndrome. Cochrane Database Syst Rev2011; 6: CD008537.
11. Gold JA, Rimal B, Nolan A, Nelson LS. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Critical care medicine, 2007; 1, 35(3): 724-30.
12. Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial. Jama, 1994; 17, 272(7): 519-23.
13. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodia zepine sforalcoh olwithdr awal. Cochrane Database Syst Rev, 2010; 3: CD005063.
14. Minozzi S, AmatoL, Vecchi S, Davoli M. Anticonvu lsantsfor alcoholw ithdrawal. Cochrane Database Syst Rev, 2010; 3: CD005064.
15. Turner RC, Lichstein PR, Peden JG, Busher JT, Waivers LE. Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. Journal of General Internal Medicine, 1989; 4: 432-44.
16. Clapp P, Bhave SV, Hoffman PL. Howadap tationofth ebraintoalco holleadstode pendence: apharmacolo gicalpe rspective. Alcohol Res Health, 2008; 31: 310–339.
17. Nejad S H, Dubovsky A, Irwin K, Fagan S, GovermanJ. Burns. In: Fogel B S, Greenberg DS, editors. Psychiatricca reofthemedic alpatient, 3rded. New York, NY: Oxford University Press, 2015; 1455–1472.
18. Moss M, Burnham EL. Alcohol abuse in the critically ill patient. The Lancet, 2006; 23, 368 (9554): 2231-42.
19. O'Brien Jr JM, Lu B, Ali NA, Martin GS, Aberegg SK, Marsh CB, Lemeshow S, Douglas IS. Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Critical care medicine, 2007; 1, 35(2): 345-50.
20. de Wit M, Jones DG, Sessler CN, Zilberberg MD, Weaver MF. Alcohol-use disorders in the critically ill patient. Chest, 2010; 1, 138(4): 994-1003.
21. Gupta N M, Lindenauer P K, Yu P CImrey P B, Haessler S, Deshpande A, etal. Associati onbetwee nalcoholu sedisor dersandout comesofpati entshospita lizedwith community-acquiredp neumonia. JAMA Netw Open, 2019; 2: e195172.
22. Caetano R, Clark CL, Greenfield TK. Prevalence, trends, and incidence of alcohol withdrawal symptoms: analysis of general population and clinical samples. Alcohol health and research world, 1998; 22(1): 73.
23. Anon. Livingin Britiain: The 2002 General Household Survey: The Officefor National Statistics, 2004.
24. Powell JE, McInness E. Alcohol use among older hospital patients: Findings from an Australian study. Drug and Alcohol Review, 1994; 1, 13(1): 5-12.
25. Conigrave KM, Burns FH, Reznik RB, etal. Proble mdrinkingi nemergency department patients: thescopefo rearlyinter vention. Med J Aust, 1991; 154: 801–5.
26. The Strategy Unit. Alcoho lmisuse: How much do esitcost? September, 2003.
27. OwensL, GilmoreI T, Pirmohamed M. How do N H Sgeneral hospitalsin England dealwithp atientswithalcoholrel atedproblems? Aquestion nairesurvey. Alcohol Alcohol, 2005; 40: 409–12.
28. Mayo-Smith MF. Pharmacologic almanagement ofalcoholw ithdrawal. Ameta-analysisa ndevidence basedpracti ceguideline. American Society of Addiction Medicine WorkingGroupon Pharma cological Management of Alcohol Withdrawal. JAMA, 1997; 278: 144–51.
29. Mayo Smith MF, Beecher L H, Fischer TL, etal. Managemen tofalcoholw ithdrawal delirium. Anevidence-based practice guideline. ArchIntern Med, 2004; 164: 1405–12.
30. Brathen G, Ben-Menachem E, Brodtkorb E, etal. EFN Sguideline onthediagno sisandmana gementofalc oholrelatedseizures: report fan EFN Staskforce. Eur J Neurol, 2005; 12: 575–81.
31. Malcolm RJ. GABA systems, benzodiazepines, and substance dependence. Journal of Clinical Psychiatry, 2003; 1, 64: 36-40.
32. Davis KM, Wu JY. Role of glutamatergic and GABAergic systems in alcoholism. Journal of Biomedical Science, 2001; 19, 8(1): 7-19.
33. Chastain G. Alcohol, neurotransmitter systems, and behavior. The Journal of general psychology, 2006; 1, 133(4): 329-35.
34. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol health and research world, 1998; 22(1): 13.
35. Nelson LS, Goldfrank LR. Goldfrank's toxicologic emergencies. (No Title), 2019.
36. Fadda F, Rossetti ZL. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Progress in neurobiology, 1998; 1, 56(4): 385-431.
37. Kattimani S, Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review. Industrial psychiatry journal, 2013; 1, 22(2): 100-8.
38. Lejoyeux M, Solomon J, Adès J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol and alcoholism, 1998; 1, 33(6): 563-75.
39. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcoholism: Clinical and experimental research, 2001; 25(9): 1324-9.
40. Maldonado JR, Sher Y, Ashouri JF, Hills-Evans K, Swendsen H, Lolak S, Miller AC. The "Prediction of Alcohol Withdrawal Severity Scale"(PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol

withdrawal syndrome. Alcohol, 2014; 1, 48(4): 375-90.
41. Malcolm R, Roberts JS, Wang W, Myrick H, Anton RF. Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol, 2000; 1, 22(3): 159-64.
42. Neuman JE, Quan D. Alcohol withdrawal syndrome. Emerg Med Rep, 2009; 30(16): 197-207.
43. Ferguson JA, Suelzer CJ, Eckert GJ, et al. Risk factors for delirium tremens development. J Gen Intern Med, 1996; 11(7): 410-414.
44. Naranjo CA, Sellers EM, Chater K, et al. Nonpharmacologic intervention in acute alcohol withdrawal. Clin Pharmacol Ther, 1983; 34(2): 214-219.
45. Blondell RD. Ambulatory detoxification of patients with alcohol dependence. Am Fam Physician, 2005; 71: 495-502.
46. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev, 2011; (6): CD008537.
47. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. Cmaj, 1999; 9, 160(5): 649-55.
48. Adinoff B. Double-blind study of alprazolam, diazepam, cloni-dine, and the placebo in the alcohol withdrawal syndrome. Alcohol Clin Exp Res, 1994; 18: 873-8.
49. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med, 2003; 348: 1786-95.
50. Ntais C, Pakos E, Kyzas P. et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev, 2005; (3): CDD005063.
51. Muzyk AJ, Leung JG, Nelson S, et al. The role of diazepam loading for the treatment of alcohol withdrawal syndrome in hospitalized patients. Am J Addict, 2013; 22: 113-8.
52. Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drug, 2014; 28: 401-10.
53. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA, 1997; 278(2): 144-151.
54. Amato L, Minozzi S, Vecchi S, et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev, 2010; (3): CD005063.
55. de Wit H, Griffths RR. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend, 1991; 28(1): 83-111.
56. Griffths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol, 1990; 10(4): 237-243.
57. Koski A, Ojanperä I, Vuori E. Alcohol and benzodiazepines in fatal poisonings. Alcohol Clin Exp Res, 2002; 26(7): 956-959.
58. Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal. JAMA, 1994; 272(7): 519-523.
59. Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med, 2002; 162(10): 1117-1121.
60. Gossop M, Keaney F, Stewart D, et al. A Short Alcohol Withdrawal Scale (SAWS). Addict Biol, 2002; 7(1): 37-43.
61. Ait-Daoud N, Malcolm RJ Jr, Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav, 2006; 31(9): 1628-1649.
62. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med, 2003; 348(18): 1786-1795.
63. Minozzi S, Amato L, Vecchi S, et al. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev, 2010; (3): CD005064.
64. Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med, 2002; 17(5): 349-355.
65. Lum E, Gorman SK, Slavik RS. Valproic acid management of acute alcohol withdrawal. Ann Pharmacother, 2006; 40(3): 441-448.
66. Schik G, Wedegaertner FR, Liersch J, et al. Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol, 2005; 10(3): 283-288.
67. Koethe D, Juelicher A, Nolden BM, et al. Oxcarbazepine—effcacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res, 2007; 31(7): 1188-1194.
68. Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res, 2009; 33(9): 1582-1588.
69. Naudet F, Braillon A. Baclofen and alcohol in France. Lancet Psychiatry, 2018; 5(12): 961–2.
70. Agabio R, Sinclair JM, Addolorato G, Aubin H-J, Beraha EM, Caputo F, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari statement. Lancet Psychiatry, 2018; 5(12): 957–60.
71. Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets, 2010; 9(1): 33–44.
72. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary

double-blind randomized controlled study.Alcohol Alcohol, 2002; 37(5): 504–8.
73. Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol, 2014; 49(6): 654–60.
74. Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction, 2018; 113(8): 1396–406.
75. Pierce M, Sutterland A, Beraha EM, Morley K, van den Brink W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol, 2018; 28(7): 795–806.
76. Minozzi S, Saulle R, Rösner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev, 2018; 11: CD012557.
77. Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction, 2017; 112(7): 1173–83.
78. Reynaud M, Aubin H-J, Trinquet F, Zakine B, Dano C, Dematteis M, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients—the ALPADIR study. Alcohol Alcohol, 2017; 52(4): 439–46.
79. Chartier M, Tannous S, Benturquia N, Labat L, Reis R, Risède P, et al. Baclofen-induced neuro-respiratory toxicity in the rat: contribution of tolerance and characterization of withdrawal syndrome. Toxicol Sci, 2018; 164(1): 153–65.
80. Santos C, Olmedo RE. Sedative-hypnotic drug withdrawal syndrome: recognition and treatment. Emerg Med Pract, 2017; 19(3): 1–20.
81. Garbutt JC, Kampov-Polevoy AB, Pedersen C, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacol, 2021; 46: 2250–6.
82. Farokhnia M, Deschaine SL, Sadighi A, Farinelli LA, Lee MR,Akhlaghi F, et al. A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Mol Psychiatry, 2021; 26(2): 545–55.
83. Morley KC, Baillie A, Fraser I, Furneaux-Bate A, Dore G, Roberts M, et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. Br J Psychiatry, 2018; 212(6): 362–9.
84. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, 2007; 370(9603): 1915–22.
85. Leggio L, Litten RZ. The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter. Neuropsyc hopharmacol, 2021; 46: 2228–9.
86. Guirguis E, Richardson J, Kuhn T, etal. Treatmen tofseve realcoholwi thdrawal: afocu sonadjunc tiveagents. J Pharm Technol, 2017; 33(5): 204-212.
87. Spies CD, Dubisz N, Neumann T, etal. Therapyof alcohol withdrawal syndromeini ntensivecar eunitpatients following trauma: resultsofa prospective, randomi zedtrial. Crit Care Med, 1996; 24(3): 414-422.
88. Rayner SG, Weinert CR, Peng H, etal. Dexmedeto midinea sadjuncttr eatmentfors everealco holwithdr awalintheI CU. AnnIntensive Care, 2012; 2(1): 12.
89. Bielka K, KuchynI, Glumcher F. Addition of dexmedetom idineto Benzodi azepines forpatien tswith alcohol withdrawal syndromeint heintensiv ecareunit: arand omizedcon trolledstudy. AnnIntensive Care, 2015; 5(1): 33.
90. Crispo AL, Daley MJ, PepinJL, etal. Comparison of clinicalout comesin nonintu batedpati entswith severeal coholwith drawalsyndr ometreated with continuousin fusionsedatives: dexme detomidineversus benzodiazepines. Pharmacotherapy, 2014; 34(9): 910-917.
91. Mueller SW, Preslaski CR, KiserTH, etal. Arandomized, double-blind, placebo-controll eddoseran gestudyof dexmedet omidineas adjunctivethe rapyforalcohol withdrawal. Crit Care Med, 2014; 42(5): 1131-1139.
92. Ludtke KA, Stanley KS, Yount NL, etal. Retrospectivere viewofcritically illpatientse xperiencingalc oholwithdrawal: dexmedetomi dineversus propofoland/ orlorazepam continuo usinfusions. Hosp Pharm, 2015; 50(3): 208-213.
93. Sanna E, Mostallino MC, Busonero F, etal. Changesin GABA (A) receptor geneexpres sionasso ciatedwithsel ectiveal terations inrecepto rfunction andpharmac ologyafter ethanolwi thdrawal. J Neurosci, 2003; 23(37): 11711-11724.
94. DubyJJ, Berry AJ, Ghayyem P, etal. Alcoholwit hdrawalsynd romeincriti callyill patients: protocolizedvers usnonprot ocolize dmanagement. J Trauma Acute Care Surg, 2014; 77(6): 938-943.
95. GoldJ A, Rimal B, Nolan A, etal. Astrategy ofescalati ngdosesofbe nzodiazepin esandpheno barbitaladministrati onreducesthe needformech anicalventilatio nindelirium tremens. Crit Care Med, 2007; 35(3): 724-730.
96. Tidwell WP, Thomas TL, Pouliot JD, etal. Treatment of alcohol ithdrawal syndrome: phenobarbitalvs CIWA-Arprotocol. Am J Crit Care, 2018; 27(6): 454-460.
97. LeeCM, Dillon DG, Tahir PM, etal. Phenobarbi taltreatm entofalcoh olwithdrawa lintheemer gencyde partment: Asystema ticreviewa ndmetaan alysis. Acad Emerg Med. Published online November, 2023; 3.

98. Ives TJ, Mooney AJ, Gwyther RE. Pharmacokineticdosing of phenobarbitalint hetreatm entofalcoho lwithdrawal syndrome. South MedJ, 1991; 84(1): 18-21.
99. Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med, 2004; 164: 1405-1412. [PubMed: 15249349].
100. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA, 1997; 278: 144-151. [PubMed: 9214531].
101. Reoux JP, Saxon AJ, Shen D. Pharmacokinetic profile of an oral loading dose of divalproex sodium during acute alcohol withdrawal. J Clin Psychopharmacol, 2006; 26: 105-[PubMed: 16415725].
102. Muncie HL Jr, Yasinian Y, Oge' L. Outpatient management of alcohol withdrawal syndrome. AmFam Physician, 2013; 88: 589-595. [PubMed: 24364635].
103. Reoux JP, Saxon AJ, Malte CA, et al. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res, 2001; 25: 1324-1329. [PubMed: 11584152].
104. Skala K, Caputo F, Mirijello A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother, 2014; 15: 245-257. [PubMed: 24283802].
105. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res, 1997; 21: 86-92. [PubMed: 9046378].
106. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry, 1998; 155: 1632. [PubMed: 9812141].
107. Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med, 2014; 174: 70-77. [PubMed: 24190578].
108. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNSDrugs, 2005; 19: 873-896. [PubMed: 16185095].
109. McLean MJ, Morrell MJ, Willmore LJ, ot al. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia, 1999; 40: 965-972. [PubMed: 104032911.
110. Choi EA, Ki SW, Kim SE, et al. The efficacy and safety of topiramate in the treatment of alcohol withdrawal. J Korean Neuropsychiatr Assoc, 2005; 44: 328-333.